ArticleCureus2024
Prevalence of Iron Deficiency Anemia in Gynecological Cancer Patients Undergoing Treatment: A Two-Institution Retrospective Study.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of anemia and iron status in Japanese patients with gynecological malignancy: retrospective cohort studyBMC women's health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnemia in patients with cancer negatively affects their quality of life and cancer outcomes. However, most patients with chemotherapy-induced anemia (CIA) are not appropriately evaluated or treated, and the prevalence of iron deficiency anemia (IDA) in CIA remains unclear.
methodsWe retrospectively reviewed the electronic records of patients with gynecological cancer in two tertiary hospitals, between March 2023 and July 2023, and evaluated their anemia status.
resultsWe identified 54 patients with CIA, and IDA was found in 74% (40/54) of patients with CIA, including 4% (2/54) with absolute iron deficiency (transferrin saturation (TSAT) < 20% and ferritin < 30 ng/mL), 63% (34/54) with functional iron deficiency (TSAT < 50% and 30 ng/mL < ferritin < 500 ng/mL), and 7% (4/54) with possible functional iron deficiency (TSAT < 50% and 500 ng/mL < ferritin < 800 ng/mL).
conclusionsWe found that 74% of patients with CIA under gynecologic cancer treatments were IDA in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.